Moderna (MRNA) Receivables - Net (2017 - 2026)

Moderna has reported Receivables - Net for 10 years, with the latest figure at $120.0 million in Q2 2026.

• Receivables - Net for Q2 2026 came in at $120.0 million, down 53.85% year-over-year; the trailing twelve-month figure through Jun 2026 was $120.0 million (down 53.85% YoY), and the FY2025 annual result was $368.0 million, down 47.28% from the prior year.
• Receivables - Net eased to $120.0 million in Q2 2026, from $203.0 million in the prior quarter.
• Over five years, Receivables - Net peaked at $3.2 billion in Q1 2022 and troughed at $120.0 million in Q2 2026.
• A 5-year average of $1.3 billion and a median of $905.5 million in 2023 frame the typical range for Receivables - Net.
• The widest annual swing landed in 2023, when Receivables - Net slumped 91.38%; it then soared 112.07% in 2024.
• A 5-year view of Receivables - Net shows it stood at $1.4 billion in 2022, then grew by 14.37% to $1.6 billion in 2023, then plunged by 55.93% to $698.0 million in 2024, then sank by 47.28% to $368.0 million in 2025, then sank by 67.39% to $120.0 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $120.0 million in Q2 2026, $203.0 million in Q1 2026, and $368.0 million in Q4 2025.